# Cerevel Therapeutics, LLC clinical trials: 22 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Cerevel Therapeutics, LLC as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Cerevel Therapeutics, LLC: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/cerevel-therapeutics-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 30, 2024 | NCT06435923 | A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of \[14C\]-Darigabat After a Single Oral Dose in Healthy Male... | Cerevel Therapeutics, LLC | Phase 1 | Completed | Healthy Participants | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06435923) |
| April 15, 2024 | NCT06366243 | A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants | Cerevel Therapeutics, LLC | Phase 1 | Completed | Healthy Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06366243) |
| March 8, 2024 | NCT06301971 | A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants | Cerevel Therapeutics, LLC | Phase 1 | Completed | Healthy Participants | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06301971) |
| July 28, 2023 | NCT05965219 | A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the... | Cerevel Therapeutics, LLC | Phase 1 | Completed | Healthy Volunteers | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05965219) |
| July 6, 2023 | NCT05933187 | A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants | Cerevel Therapeutics, LLC | Phase 1 | Completed | Healthy Participants | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05933187) |
| June 23, 2023 | NCT05915546 | The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants | Cerevel Therapeutics, LLC | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05915546) |
| April 21, 2023 | NCT05824143 | Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants | Cerevel Therapeutics, LLC | Phase 1 | Completed | Healthy Participants | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05824143) |
| November 9, 2022 | NCT05610189 | Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease | Cerevel Therapeutics, LLC | Phase 1 | Completed | Parkinson Disease | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05610189) |
| October 17, 2022 | NCT05581823 | Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants | Cerevel Therapeutics, LLC | Phase 1 | Completed | Parkinson Disease | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05581823) |
| September 21, 2022 | NCT05547542 | Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral... | Cerevel Therapeutics, LLC | Phase 1 | Completed | Opioid Use Disorder | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05547542) |
| June 3, 2022 | NCT05404542 | To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal... | Cerevel Therapeutics, LLC | Phase 1 | Completed | Renal Impairment | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05404542) |
| June 3, 2022 | NCT05404529 | To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to... | Cerevel Therapeutics, LLC | Phase 1 | Completed | Hepatic Impairment | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05404529) |
| February 18, 2022 | NCT05245539 | Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia | Cerevel Therapeutics, LLC | Phase 1 | Completed | Blood Pressure, Schizophrenia | 151 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05245539) |
| December 1, 2021 | NCT05138653 | A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants | Cerevel Therapeutics, LLC | Phase 1 | Completed | Healthy Participants | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05138653) |
| November 17, 2021 | NCT05123079 | Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants | Cerevel Therapeutics, LLC | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05123079) |
| November 3, 2021 | NCT05106309 | Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy... | Cerevel Therapeutics, LLC | Phase 1 | Completed | Schizophrenia | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05106309) |
| March 8, 2021 | NCT04787302 | PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing | Cerevel Therapeutics, LLC | Phase 1 | Completed | Schizophrenia | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04787302) |
| October 19, 2020 | NCT04592536 | A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects | Cerevel Therapeutics, LLC | Phase 1 | Completed | Panic Disorder | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04592536) |
| March 4, 2020 | NCT04295642 | A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease | Cerevel Therapeutics, LLC | Phase 1 | Completed | Parkinson Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04295642) |
| January 27, 2020 | NCT04241393 | An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects | Cerevel Therapeutics, LLC | Phase 1 | Completed | Healthy Subjects | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04241393) |
| January 18, 2020 | NCT04232878 | A Single Ascending Dose Trial of CVL-936 in Healthy Subjects | Cerevel Therapeutics, LLC | Phase 1 | Terminated | Substance Use Disorders (SUD) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04232878) |
| October 23, 2019 | NCT04136873 | A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia | Cerevel Therapeutics, LLC | Phase 1 | Completed | Schizophrenia | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04136873) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 22 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 4 |
| Parkinson Disease | 3 |
| Panic Disorder | 1 |
| Anxiety Disorders | 1 |
| Hypercapnia | 1 |
| Parkinsonian Disorders | 1 |
| Brain Diseases | 1 |
| Central Nervous System Diseases | 1 |
| Nervous System Diseases | 1 |
| Movement Disorders | 1 |
| Neurodegenerative Diseases | 1 |
| Opioid-Related Disorders | 1 |
| Schizophrenia Spectrum and Other Psychotic Disorders | 1 |
| Mental Disorders | 1 |
| Substance-Related Disorders | 1 |
| Renal Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Home network installers in the United States](https://specstream.ai/data/businesses/home-network-installers/united-states)
- [Belgian restaurants in the United States](https://specstream.ai/data/businesses/belgian-restaurants/united-states)
- [Russian restaurants in the United States](https://specstream.ai/data/businesses/russian-restaurants/united-states)
- [Hostels in the United States](https://specstream.ai/data/businesses/hostels/united-states)
- [Book magazine distribution companies in the United States](https://specstream.ai/data/businesses/book-magazine-distribution-companies/united-states)
- [Scandinavian restaurants in the United States](https://specstream.ai/data/businesses/scandinavian-restaurants/united-states)
